- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04843969
Investigation of Cigarette Cravings in Smokers
Investigating Stress-Potentiated Memory Updating as a Novel Intervention for Non-Treatment Seeking Smokers
Interventions to disrupt memory reconsolidation have held promise for the treatment of stress- and anxiety-related disorders. In the present study, the investigators will examine whether an intervention based on these principles, called memory updating, could be adapted for reward-seeking behaviors. To test this, non-treatment seeking tobacco smokers will be exposed to smoking cues and/or stress, two stimuli known to trigger smoking. It is predicted that exposure to a stress task will enhance the cues' motivational salience and yield greater susceptibility to the memory updating procedure.
As an add-on, the investigators will examine COVID-associated changes in substance use and whether participants in the memory updating groups might be more resilient to these effects. It is predicted that the changes in substance use will depend on whether the substances are used primarily in social settings.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Non-treatment seeking cigarette dependent smokers will be randomized to one of four testing conditions: 1) a non-stressful task followed by neutral cues, 2) the non-stressful task followed by smoking cues, 3) a stressful task followed by neutral cues, or 4) the stressful task followed by smoking cues. Ten minutes after the intervention, participants will undergo a 60-minute extinction procedure consisting of smoking-related videos, images and smoking paraphernalia. Cue reactivity test sessions will take place 24 hours, 2 weeks and 6 weeks following the intervention.
COVID-associated changes in substance use will be quantified over three telephone interviews: one at the end of March / beginning of April 2020 (at the start of the pandemic), one at the end of April / beginning of May, and a final one which will be instituted if feasible once the infection rates and social distancing policies have decreased.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Quebec
-
Montreal, Quebec, Kanada, H3A 1A1
- McGill University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Scoring 5 or higher on the Fagerström Test for Cigarette Dependence
- Willingness to abstain from smoking for 4 hours prior to each laboratory visit
Exclusion Criteria:
- Currently using cigarette cessation products
- Endocrinological problems
- Significant mental or physical health conditions
- Pregnancy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Stress task and smoking cue
Exposure to a psychosocial stress task followed by smoking video cues
|
Exposure to a psychosocial stressor
Exposure to a smoking-related task
|
|
Experimental: Stress task and neutral cue
Exposure to a psychosocial stress task followed by neutral video cues
|
Exposure to a psychosocial stressor
Exposure to neutral cues
|
|
Aktiver Komparator: Control task and smoking cue
Exposure to a control task followed by smoking video cues
|
Exposure to a smoking-related task
Exposure to a control task (no stress)
|
|
Aktiver Komparator: Control task and neutral cue
Exposure to a control task followed by neutral video cues
|
Exposure to neutral cues
Exposure to a control task (no stress)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in cigarettes smoked per day from the pre-intervention baseline to test sessions 2 and 3 given two and six weeks post-intervention
Zeitfenster: At the end of test session 1 (24 hours post-intervention), participants will receive a journal to record their daily smoking behaviour. They are asked to keep this journal until test session 3 (6 weeks post-intervention).
|
A journal is given to participants to record their cigarette use behaviour every day for a month and a half
|
At the end of test session 1 (24 hours post-intervention), participants will receive a journal to record their daily smoking behaviour. They are asked to keep this journal until test session 3 (6 weeks post-intervention).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in smoking cue-induced cigarette cravings from the pre-intervention baseline to test session 2
Zeitfenster: Multiple times points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention.
|
Participants will be asked to complete craving and urge to smoke questionnaires at several time points throughout the study sessions
|
Multiple times points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention.
|
|
Change in smoking cue-induced cigarette cravings from the pre-intervention baseline to test session 3
Zeitfenster: Multiple times points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention.
|
Participants will be asked to complete craving and urge to smoke questionnaires at several time points throughout the study sessions
|
Multiple times points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention.
|
|
Change in smoking cue-induced heart rate responses from the pre-intervention baseline to test session 2
Zeitfenster: Multiple time points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
Participants' heart rate will be measured through the use of a polar belt at several time points during the study sessions
|
Multiple time points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
|
Change in smoking cue-induced heart rate responses from the pre-intervention baseline to test session 3
Zeitfenster: Multiple time points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
Participants' heart rate will be measured through the use of a polar belt at several time points during the study sessions
|
Multiple time points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
|
Change in smoking cue-induced skin conductance responses from the pre-intervention baseline to test session 2
Zeitfenster: Multiple time points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
Participants' skin conductance will be measured through the use of electrodes on their index and middle fingers at several time points during the study sessions
|
Multiple time points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
|
Change in smoking cue-induced skin conductance responses from the pre-intervention baseline to test session 3
Zeitfenster: Multiple time points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
Participants' skin conductance will be measured through the use of electrodes on their index and middle fingers at several time points during the study sessions
|
Multiple time points during the baseline, intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
|
Change in tobacco and other substance use patterns from the pre-COVID-19 baseline to during COVID-19
Zeitfenster: Multiple time points at baseline (before the pandemic), at the start of the pandemic, and during the pandemic
|
Participants will be asked to report the quantity of cigarettes and/or other substances they have consumed recently
|
Multiple time points at baseline (before the pandemic), at the start of the pandemic, and during the pandemic
|
|
Change in tobacco and other substance use patterns from the pre-COVID-19 baseline to post-COVID-19
Zeitfenster: At baseline (before the pandemic) and through study completion, an average of 1 year
|
Participants will be asked to report the quantity of cigarettes and/or other substances they have consumed recently
|
At baseline (before the pandemic) and through study completion, an average of 1 year
|
|
Change in tobacco and other substance use patterns during the COVID-19 pandemic to post-COVID-19
Zeitfenster: Multiple time points during the pandemic and through study completion, an average of 1 year
|
Participants will be asked to report the quantity of cigarettes and/or other substances they have consumed recently
|
Multiple time points during the pandemic and through study completion, an average of 1 year
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in stress- and/or cue-induced mood during the intervention and at test sessions 1, 2 and 3
Zeitfenster: Multiple time points during the intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
Participants will be asked to complete a mood questionnaire at several time points during the intervention and at test sessions 1, 2 and 3
|
Multiple time points during the intervention and test sessions at 24 hours, 2 weeks and 6 weeks post-intervention
|
|
Change in cigarette use over the course of the procedure as a function of personality factors, childhood trauma, perceived stress, mood and/or cigarette withdrawal
Zeitfenster: Multiple time points at baseline, during the intervention, at test sessions (24 hours, 2 weeks and 6 weeks post-intervention) and telephone follow-ups (6 months post-intervention)
|
Participants will be asked to complete self-report questionnaires about their personality traits, traumatic childhood experiences, perceived stress, current mood states and cigarette withdrawal symptoms
|
Multiple time points at baseline, during the intervention, at test sessions (24 hours, 2 weeks and 6 weeks post-intervention) and telephone follow-ups (6 months post-intervention)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Marco Leyton, PhD, McGill University
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 421-0318
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Tabakkonsum
-
University of KonstanzAfrica Mental Health FoundationAbgeschlossenKhat-Use-StörungKenia
-
University of North Carolina, Chapel HillRekrutierungOff-Label-Use von Medikamenten bei pädiatrischen PatientenVereinigte Staaten
-
University of Massachusetts, WorcesterAgency for Healthcare Research and Quality (AHRQ); Omnicare Clinical Research; Qualidig...AbgeschlossenOff-Label-Use von atypischen AntipsychotikaVereinigte Staaten
-
University of KonstanzAfrica Mental Health FoundationAbgeschlossenPosttraumatische Belastungsstörung | Khat-Use-StörungKenia
Klinische Studien zur Stress induction
-
Inonu UniversityAbgeschlossenSmartphone-SüchteTürkei (türkiye)
-
Huzhou UniversityAbgeschlossenKrankenschwester | Psychiatrisch | Stress -ImpfungstrainingChina
-
University of California, IrvineEunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenStress, Psychisch | Schwangerschaft bezogen | Insulinsensitivität/-resistenz | Emotionaler Stress | Postprandiale Hyperglykämie | Glukoseintoleranz während der SchwangerschaftVereinigte Staaten
-
Walter Reed Army Medical CenterUnbekanntKoronare Herzkrankheit | Brustschmerzen | Koronare atherosklerose | BelastbarkeitstestVereinigte Staaten
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell UniversityAbgeschlossenHodgkin-Lymphom-ÜberlebenderVereinigte Staaten
-
Clinica Alemana de SantiagoUniversidad del DesarrolloRekrutierungAngst | Einleitung der Anästhesie | Angst vor der Operation | Technologienutzung | Kindliche Angst | Anästhesieversorgung | Angst nach der OperationChile
-
Massachusetts General HospitalUnited States Department of DefenseAktiv, nicht rekrutierend
-
Research on Healthcare Performance Lab U1290RekrutierungBetonen | Gesundheitsverhalten | Gesundheitsbezogenes VerhaltenFrankreich
-
The University of Hong KongRekrutierung
-
Massachusetts General HospitalUnited States Department of DefenseAbgeschlossenNeurofibromatosen | Neurofibromatose 1 | Neurofibromatose 2 | SchwannomatoseVereinigte Staaten